NCT01815528

Feasibility and Clinical Activity of Initial Intraperitoneal Catumaxomab Followed by Chemotherapy in Patients With Recurrent Ovarian Cancer

Single -Arm, Multicenter Phase-II Trial for Catumaxomab and Chemotherapy in Patients With Recurrent Ovarian Cancer to Investigate the Feasibility and Clinical Activity of Initial Intraperitoneal Catumaxomab Followed by Chemotherapy Regimes

• Status: Completed
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 2 (actual)
• Sponsor: JSehouli · Academic / Other
• Sex: Female
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

Single -arm, multicenter phase-II trial for catumaxomab and chemotherapy in patients with recurrent ovarian cancer to investigate the feasibility and clinical activity of initial intraperitoneal catumaxomab followed by chemotherapy regimes.

Conditions

• Recurrent Epithelial Ovarian Cancer

Interventions

Type	Name	Description
DRUG	Catumaxomab	Catumaxomab dosing comprises the following four intraperitoneal (i.p.) infusions via an i.p.-port or an indwelling catheter: 1. 10 µg on day 0 2. 20 µg on day 3 3. 50 µg on day 7 4. 150 µg on day 10

Timeline

• Start date: 2013-03-01
• Primary completion: 2014-02-01
• Completion: 2014-02-01
• First posted: 2013-03-21
• Last updated: 2015-02-18

Locations

1 site across 1 country: Germany